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Abstract
Background: Pulmonary-delivered gene therapy promises to mitigate vaccine safety issues and reduce the need for
needles and skilled personnel to use them. While plasmid DNA (pDNA) offers a rapid route to vaccine production
without side effects or reliance on cold chain storage, its delivery to the lung has proved challenging. Conventional
methods, including jet and ultrasonic nebulizers, fail to deliver large biomolecules like pDNA intact due to the shear
and cavitational stresses present during nebulization.
Methods: In vitro structural analysis followed by in vivo protein expression studies served in assessing the integrity of
the pDNA subjected to surface acoustic wave (SAW) nebulisation. In vivo immunization trials were then carried out in
rats using SAW nebulized pDNA (influenza A, human hemagglutinin H1N1) condensate delivered via intratracheal
instillation. Finally, in vivo pulmonary vaccinations using pDNA for influenza was nebulized and delivered via a
respirator to sheep.
Results: The SAW nebulizer was effective at generating pDNA aerosols with sizes optimal for deep lung delivery.
Successful gene expression was observed in mouse lung epithelial cells, when SAW-nebulized pDNA was delivered to
male Swiss mice via intratracheal instillation. Effective systemic and mucosal antibody responses were found in rats via
post-nebulized, condensed fluid instillation. Significantly, we demonstrated the suitability of the SAW nebulizer to
administer unprotected pDNA encoding an influenza A virus surface glycoprotein to respirated sheep via aerosolized
inhalation.
Conclusion: Given the difficulty of inducing functional antibody responses for DNA vaccination in large animals, we
report here the first instance of successful aerosolized inhalation delivery of a pDNA vaccine in a large animal model
relevant to human lung development, structure, physiology, and disease, using a novel, low-power (<1 W) surface
acoustic wave (SAW) hand-held nebulizer to produce droplets of pDNA with a size range suitable for delivery to the
lower respiratory airways.
Keywords: Gene therapy, Surface acoustic wave, Nebulization
*Correspondence: james.friend@rmit.edu.au
3RMIT University, Micro Nano Research Facility, 124 La Trobe Street, 3000
Melbourne, Australia
4Melbourne Centre for Nanofabrication, 151 Wellington Road, 3800 Clayton,
Australia
Full list of author information is available at the end of the article
© 2014 Rajapaksa et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication
waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise
stated.
Rajapaksa et al. Respiratory Research 2014, 15:60 Page 2 of 12
http://respiratory-research.com/content/15/1/60
Background
The lung is an attractive site for delivery of gene ther-
apy and DNA vaccine agents since it is accessible, has
a large surface area and is highly cellular and vascular-
ized to facilitate transfection. Further, pulmonary delivery
via inhalation is non-invasive and allows for pain-free
access where potential systemic side effects areminimized
[1,2]. Replacement of the parenteral route with alter-
native modes of administration would mitigate vaccine
safety issues and the requirement for skilled personnel,
amongst the many other issues associated with injections
[3,4]. Indeed, there has been significant interest to date in
the potential of pulmonary gene therapy in treating pul-
monary diseases caused by single gene mutation such as
cystic fibrosis and 1-antitrypsin deficiency [5]. Further,
there is potential for pulmonary vaccination to be use-
ful against a range of pathogens, since immunity can be
induced at mucosal sites through which these agents enter
the body [2].
Effective pulmonary administration of DNA demon-
strating cellular or tissue expression and subsequent
induction of protective immunity has been a challeng-
ing task. Aerosols containing plasmid DNA (pDNA) can
reach and adhere to the bronchial and alveolar epithelial
cells only if the aerosol droplets are between 1 and 5 μm,
enabling pDNA entry and subsequent gene expression [6].
Recent work nevertheless suggests delivery via themucosa
may be more feasible than once thought [7].
While nebulizers are the delivery method of choice for
macromolecules [6], delivery of non-complexed pDNA
is impractical in current nebulizers due to poor droplet
size control as well as the generation of sufficient
hydrodynamic stresses that can shear pDNA molecules
(>5 kbp) into open circular and fragmented configura-
tions [8-10]. The transfection efficiency of such post-
nebulized DNA has been shown to be as low as 10%,
which often necessitates complexation of the DNA in
an attempt to protect it from shear-induced degrada-
tion [11]. For example, the pulmonary delivery of cationic
polymers has led to modestly improved gene expres-
sion in the airways of sheep [12,13]. However, not all
polyplexes (nor lipoplexes) retain biological efficacy after
aerosolization [14], with some commonly used synthetic
polymers such as polyethylenimine (PEI) considered to
be cytotoxic [15]. Effective delivery via the pulmonary
route therefore requires the aerosolized DNA to be
internalized into the target cell via endocytosis, avoid-
ing degradation either during delivery or via exposure
to lysosomal or cytoplasmic nucleases, and subsequent
transcription and translation to produce the desired gene
product [16].
Surface acoustic wave (SAW) nebulization was recently
shown to effectively form aerosols of a short acting β2-
agonist with a respirable fraction of >70% [17], much
more than the typical 30–40% lung dose available via
current nebulizers [18]. Rayleigh SAWs, transverse-axial
polarized electroacoustic waves generated by a sinusoidal
electric field between the interlaced fingers of an interdig-
ital transducer (IDT) electrode, are formed and propagate
at nanometer amplitudes at MHz to GHz-order frequen-
cies along piezoelectric lithium niobate (LiNbO3). In such
devices, the SAW is localized to the substrate surface, and
most of the energy input into the system is near the surface
and transferred into fluid resting upon it with minimal
loss. As such, SAW nebulization requires only about 1 W
of power to operate, significantly less than conventional
bulk piezoelectric ultrasonic radiators, and convenient for
use in handheld devices [19].
The aim of this study was to demonstrate the feasibility
of SAW nebulization as an aerosol delivery platform for
DNA delivery to the lungs in a large animal model.
Methods
Preparation of pDNA
The mouse malaria P. yoelli merozoite surface protein
4/5 (PyMSP4/5) was cloned into the mammalian expres-
sion vector pVR1020 and was used throughout the in
vitro work [20]. The VR1020 plasmid encoding yellow
florescent protein (YFP) that replaced the PyMSP4/5
gene was used for the in vivo studies to aid visual-
ization of the gene expression. For the immunization
trial, a plasmid DNA was prepared from a gene encod-
ing an influenza A virus surface hemagglutinin protein,
human hemagglutinin (A/Solomon Islands/3/2006 (egg
passage) (H1N1) strain), once cloned into the mam-
malian expression vector pVR1020 (Vical Inc., USA).
The entire coding sequence of HA was amplified by
PCR using primers forward and reverse that incorpo-
rated a BamHI site at the 5’ end and a EcoRI site at the
3’ end, forward: 5’-CGCGGATCCATGAAAGTAAAAC
TACTGGTCCTGTTATG-3’; reverse: 5’-CCGGAATTC
TTGTTTGTAATCCCATTAATGGCATTTTGT-3’. The
PCR product was digested with BamHI/EcoRI and lig-
ated into the vector, pVR1020, resulting the in plasmid
pVR1020–HA.
A colony of E. coli DH5α harboring either plasmid
pVR1020–PyMSP4/5 (∼5.6 kbp), pVR1020–YFP (∼5.7
kbp) or pVR1020–HA (∼6 kbp) was picked from a
streaked selective plate and inoculated in 10 ml of LB
medium containing 100.0 μg/ml of kanamycin. The
starter culture was incubated at 37°C and agitated at
200 rpm for 8 h before being transferred to five sep-
arated 200 ml LB media, and further cultured for 12
h. The cell cultures were stored at −70°C for subse-
quent use. The plasmids were purified from cells using
an endotoxin-free plasmid purification kit (QIAGEN
Mega, Australia) according to the manufacturer’s
instructions.
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SAW nebulization of Plasmid DNA
Different concentrations of pDNA solution (5–85 μg/ml
in deionized water for pVR1020–PyMSP4/5 and 1.5
mg/ml in 0.9% NaCl for pVR1020–YFP) were nebulized
using both 20 and 30 MHz SAW devices at approximately
110 μ/min and carefully collected in microcentrifuge
tubes for further analysis as illustrated in Figure 1. The
concentration of pDNA in the collected samples was
determined by a UV spectrophotometer (NanoDrop 1000,
Thermo Scientific, USA) at a wavelength of 260 nm. The
purity of pDNA samples was assessed by the samples’
absorbance at 260 and 280 nm.
Agarose gel electrophoresis
Both control and nebulized pDNA samples were analyzed
for potential alterations in the plasmid structure with 0.8%
agarose gel electrophoresis that used a 1 kbp DNA lad-
der and ethidium bromide (EtBr) staining [21]. The gel
was made up of 0.8 g agarose at 50× dilution of TAE
buffer (242.0 g Tris base, 57.1 ml CH3COOH, 9.3 g of
Figure 1 Collecting nebulized pDNA from the SAW nebuliser. A
pDNA-laden meniscus forms at the end of the cellulose fiber wick
upon the activation of the SAW nebulizer at the tip of the fiber wick
and nebulizes inside the vial.
EDTA). The gel was stained with 3 μg/ml EtBr and the
electrophoresis was carried out under 60 V for 90 min.
The resulting gel was analyzed and imaged in a Molecu-
lar Imager Gel Doc XR system (Bio-Rad, Australia). The
intensity of the bands for each structure corresponds to
the number of DNA molecules. The percentage of super-
coiled (SC) and open circular (OC) to degraded linear
pDNA was quantified via densitometry software (Quan-
tity One, Bio-Rad, Australia) by comparing pre- and post-
nebulized samples. However, it was found that the binding
of EtBr to different plasmid structures is dependent on the
DNA topology, and a correction factor of 1.36 was there-
fore multiplied against the measured fluorescence values
of the supercoiled structure [22].
AFM imaging of pDNA
A freshly cleaved 10 mm diameter mica disc was coated
with 10 μl of 10 mM Ni(NO3)2 to render the mica surface
cationic for adsorption of anionic pDNA. Tenμl of pDNA
solution (6–25μg/ml) was pipetted onto themica surface.
Two to five minutes were allowed to elapse to enable the
pDNA to absorb onto the surface, after which the mica
disc was rinsed with ultra-pure water and dried under a
gentle stream of N2 gas prior to AFM imaging. The sur-
face morphology of pDNA was imaged with an Ntegra
Scanning Probe Laboratory (NT–MDT, Zelenograd, Rus-
sia) operating in intermittent contact (or tapping) mode in
air using MikroMasch NSC15 probes [23]. Images of 512
× 512 pixels with a scan size of 3 × 3, 1 × 1 and 0.5 × 0.5
μm2 were acquired at scan rates of 1–2 Hz. AFM images
were processed to correct plane tilt, arcing and line fluc-
tuations. For the presented images, 3 × 3 Gaussian noise
filtering and 3D rendering was also applied using WsXM
freeware (version 5, build 1.1, Nanotec Electronica S.L.,
Spain).
Aerosol characterization
De Brouckere (volume moment, D43) mean diameter is
the average particle size relevant to the dose’s delivery
efficiency when the particles are droplets of unit density.
To examine the aerosol size distribution of the nebulized
pDNA, pVR1020–PyMSP4/5 was prepared in glycerol and
the aerosol size for different preparations was character-
ized by laser diffraction (Spraytec, Malvern Instruments,
UK) following nebulization using the SAW device. In
order to characterize the pDNA aerosol size distribution,
D43 was recorded during the measurements.
Animal trials
For gene expression detection studies, male Swiss mice
(8–10 week old) were used, weighing 37–40 g, and for the
genetic immunization trial via intratracheal instillation,
female Sprague-Dawley rats (8–10 week old), weighing
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241–270 g, were purchased from Animal Resources Centre
(Canning Vale, Australia). Mice and rats were housed under
specific pathogen-free conditions at the Monash Insti-
tute of Pharmaceutical Sciences animal facility (Parkville,
Australia) and had access to food and water ad libitum.
For the DNA vaccination of sheep via inhalation, female
Merino-cross ewe lambs (5-6 months of age) used in
these studies were housed in pens (Department of Physiol-
ogy animal facility, Clayton, Australia) and fed ad libitum
and judged free of significant pulmonary disease on the
basis of clinical examination. All experimental animal pro-
cedures were approved by the Animal Experimentation
Ethics Committee of Monash University, following guide-
lines set by the National Health and Medical Research
Council (NHMRC) of Australia.
Gene expression in vivo following intratracheal plasmid
DNA delivery in mice
For in vivo transfection, the mice were anesthetized by
intraperitoneal injection of 100 mg/kg body weight of
ketamine (Parnell Laboratories, Australia) and 10 mg/kg
body weight of xylazine (Tony Laboratories, Australia). A
solution of sterile pVR1020 encoding YFP in 0.9% NaCl
at a concentration of 1.5 mg/ml was nebulized using a
30 MHz SAW nebulizer and the condensed aerosol con-
taining the nebulized plasmid was carefully collected as
described earlier. For intratracheal instillation, the mice
were suspended at 45 degrees by the upper teeth on a
rodent dosing board and the trachea was visualized using
a fiber optic stylet connected to an endotracheal tube (Bio-
lite small animal intubation system, Kent Scientific Corp,
USA). The trachea was intubated and post-nebulized plas-
mid in saline (50 μl) was delivered followed by 200 μl of
air. Themice were sacrificed 24 hours later, and their lungs
were harvested and subsequently frozen in Jung tissue
freezingmedium (LeicaMicrosystems,Germany) for later
analysis of tissue sections. Cryosections (10 μm) cut onto
glass microscope slides were fixed with 1% paraformalde-
hyde, mounted with mowiol (4–88 Reagent from Cal-
biochem, Australia) solution to which 4’,6-diamidino–2–
phenylindole dilactate (DAPI, dilactate) was added, and
subsequently examined under a confocal laser scanning
microscope (A1, Nikon Instruments Inc., Japan) for YFP
gene expression. Lung and airway morphology was exam-
ined on adjacent sections with hematoxylin and eosin. As
additional confirmation for the detection of YFP in the
mice lungs, the lung samples were homogenized using
lysis buffer containing 50 mM Tris (pH 7.5), 100 mM
NaCl and 1% Triton X–100. The homogenate was then
centrifuged and the supernatant was used for Western
blot detection [24] of the YFP protein where SDS-PAGE
and immunoblotting analysis procedures were carried out
as previously described, except that the membranes were
probed with rabbit anti-YFP antisera.
Pulmonary intratracheal vaccinations using pre-SAW
nebulized plasmid DNA in rats
For pulmonary vaccinations, solution of sterile pVR1020
encoding HA in 5% dextrose at a concentration of 300
μg/ml was nebulized at approximately 110 μl/min using
a 30 MHz device and the condensed aerosol containing
the nebulized plasmid was carefully collected as described
earlier. Rat immunizations were carried out using the
intratracheal instillation technique also described earlier
where the trachea of the rats were intubated and 300 μg
of post-nebulized plasmid in 5% dextrose (n = 8, post-
nebulized group), 300 μg of pre-nebulized plasmid in 5%
dextrose (n = 8, pre-nebulized group), and 5% dextrose
(n = 8, naïve group) in a total volume of 100 μl was
delivered followed by 200μl of air. Subsequent immuniza-
tions were carried out 2 weeks (secondary) and 3 weeks
(tertiary) after the primary immunization. Serum was col-
lected prior to the commencement of the study and 5
weeks after the first immunization. Blood was collected
from the tail vein, then left to coagulate for the collection
of sera and stored at −20°C until further analyzed.
Pulmonary DNA inhalation vaccination using SAW
nebulization in sheep
Sheep (n = 4) were immunized via inhalation through
an endotracheal tube inserted through the nostril with
sterile pVR1020 encoding HA in 5% dextrose at a con-
centration of 85 μg/ml, nebulized using a 30 MHz SAW
device in a chamber placed in line with the inspiratory
limb of the mechanical ventilator (ventilator Model 55-
0723; Harvard Apparatus, MA) set at 20 breaths/min at
50% inspiration for 20-30 minutes (as per Figure 2). Two
bacterial/viral filters (Hudson RCI, USA) and two low flow
resistance, Hudson one-way valves (Hudson RCI, USA)
were placed at each end of the inspiratory and expira-
tory limbs in line with the rest of the connecting tubing.
In order to calculate the delivered mass of pDNA to the
ovine lung, all tubing, including the filters and valves,
were carefully washed with deionized water to recoup
any pDNA present, if any, and subsequently quantified
via a UV spectrophotometer described earlier. Subsequent
immunizations were carried out 3 weeks (secondary) and
6 weeks (tertiary) after the primary immunization. Serum
from peripheral blood samples collected prior to the
commencement of the study and 1 week after the last
immunization were stored frozen prior to determination
of hemagglutination inhibition activity.
Evaluation of antibody responses by enzyme-linked
immunosorbent assay
For the detection of anti-influenza (HA) antibodies in
the serum samples, enzyme-linked immunosorbent assays
(ELISAs) [25] were performed in 96-well MaxiSorp
plates (Nunc, Denmark). Plates were coated with 0.05
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Figure 2 Schematic drawing of the pulmonary delivery system used for aerosolized pDNA administration in conscious sheep via
inhalation. Room air was drawn through a bacterial/viral filter and a one-way valve placed in the inspiratory limb. Nebulized plasmid DNA was
introduced into the inspiratory arm of the system via the 30 MHz SAW device positioned in a chamber in line with a mechanical ventilator to
facilitate controlled respiration in sheep. The closed respiratory circuit was completed with the placement of an endotracheal tube via the nasal
passage. Each sheep received three immunizations, once (20-30minute aerosolization) per three-week period, with a pDNA aerosol containing
sterile pVR1020 encoding HA (85 μg/ml) in 5% dextrose.
μg HA protein (Immune Technology Corp., USA) in
carbonate coating buffer (0.015 M Na2CO3, 0.035 M
NaHCO3, 0.003 M NaN3, pH 9.6) and blocked with
2% w/v skim milk powder. Serial 2-fold dilutions of
serum samples were added in duplicate followed by
anti-sheep IgG horseradish peroxidase (HRP) conju-
gated immunoglobulin (DAKO, Denmark) or dilution of
anti-sheep IgA horseradish peroxidase (HRP) conjugated
immunoglobulin (AbCam, Australia). Plates were devel-
oped with 3,3’,5,5’–tetramethylbenzidine (TMB) (Sigma
Aldrich, Australia) substrate. Absorbance was measured
at 450 nm and endpoint titers were calculated.
Serum evaluation of hemagglutination inhibition activity
The serum samples collected from immunized sheep and
rats were tested for inhibition activity against four hemag-
glutinating units (HAU) of A/Solomon Islands/3/2006
virus in microtiter plates at room temperature using 1%
v/v chicken erythrocytes [26]. Virus-induced hemaggluti-
nation titers were determined as the minimum dilution of
samples required to inhibit hemagglutinating activity of
four HAU of virus.
Statistical analysis
Statistical analyses were performed using SPSS (IBM
Corporation, Armonk, USA). One-way ANOVA with a
Tukey’s post-hoc test was used for data that survived
Shapiro-Wilk’s (SW) normality test with significance p >
0.05. In instances where the SW test was significant (p <
0.05), the non-parametric Kruskal-Wallis (KW) test was
used instead to test for the overall significance between
independent groups. Where differences were observed,
Mann-Whitney (MW) tests were performed between two
independent samples to identify the differences. All data
are expressed as the mean ± standard deviation. The
results were considered significant if p < 0.05.
Results
SAW nebulized pDNA displays aerosol size characteristics
to suit deep lung deposition
Our initial investigations sought to determine the aerosol
size distribution of the nebulized pDNA (PyMSP4/5), pre-
pared in glycerol, including the desired 1–5 μm range for
pulmonary delivery. As seen in Figure 3, the pDNA formu-
lation at 100 μg/ml with glycerol concentrations of 10%,
20% and 40% enabled average droplet size distributions
under 5μm to be reliably achieved. Increasing the concen-
tration of glycerol was seen to reduce the average aerosol
diameter for a fixed pDNA concentration (Table 1), thus
confirming our ability to establish some control over the
desired aerosol dimension through the physical properties
of the liquid.
SAW nebulization preserves integrity of pDNA
The structural integrity of pDNA plays a key role in
preserving the bio-activity where AFM imaging and
agarose gel electrophoresis was used for structural anal-
ysis of pDNA encoding PyMSP4/5 before and after
SAW nebulization. AFM imaging revealed that the non-
nebulized plasmid DNA showed a tightly twisted super-
coiled geometry, with few relaxed strands (open circular
structures) (Figure 4(a)), characteristic morphologies for
uncondensed plasmids [27]. A representative image of
the SAW nebulized pDNA showed some aggregated
structures and some relaxed open loop structures with
little fragmented strands (Figure 4(b)). These structural
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Figure 3Measured using laser diffraction (Spraytec, Malvern, UK), the size distribution of nebulized droplets using SAW at 30 MHz and
1W of applied power from an aqueous suspensions of 10, 50 and 100 µg/ml of pDNA indicates droplet size distributions generally less
than 5µm, useful for deep lung deposition.
characteristics were further confirmed upon examination
of the pDNA preparations by agarose gel electrophoresis,
where changes in the supercoiled, open circular and frag-
mented pDNA structures prior to and after nebulization
were observed (Figure 4(c)). Significantly, the unprotected
naked pDNA was preserved during the SAW nebulization
process, and in most cases more than 90% of the ini-
tial supercoiled pDNA was still present post-nebulization
(Figure 4(d)).
Airway administration of nebulized pDNA induces gene
expression in themurine lung
Mice were used to assess gene expression following
SAW-nebulized airway administration of pDNA encoding
yellow fluorescent protein (YFP) (Figure 5(a)-(f )). Scat-
tered, indiscriminate YFP expression was observed in the
mouse lung when examined 24 hours following intratra-
cheal instillation with condensed nebulized pVR1020-YFP
(Figure 5(c)). Importantly, YFP expression was absent
in the untreated mouse lung (Figure 5(f )). YFP-positive
cells detected in the mouse lung were mainly located
close to the epithelium of the conducting airways, where
there appeared to be discrete aggregates of YFP protein
(Figure 6(a)-(c)). Further confirmation of YFP expression
in the murine lung was demonstrated in Western blot
Table 1 Mean aerosol droplet diameter for the SAW
nebulizer
pDNA concentration (µg/ml) %w/w glycerol D43 (µm)
100 0 8.25± 0.34
10 7.61± 0.94
20 4.12± 0.13
50 20 5.49± 0.10
10 20 4.08± 0.02
analysis of lung tissue collected 24 hours post-pDNA
administration (Figure 6(d)).
No tissue damage was evident in the mouse lungs
instilled with SAW-nebulized pDNA (as indicated by the
absence of hemosiderin deposits in tissue sections stained
with Perl′s Prussian blue) and was confirmed by the lack
of inflammatory cells and lack of micro-haemorrhaging in
the lung tissue (data not shown).
Lung pDNA vaccination induces serum antibody responses
and HAI activity in rats
Sprague Dawley rats were used as a suitable small animal
model for infuenza [28]. To examine antibody responses
to pDNA vaccination (pVR1020 encoding HA) via intra-
tracheal instillation in rats, ELISAs were performed on
sera collected prior to and two weeks after a third airway
immunization. Significant increases in both IgG and IgA
antibody titer levels against the influenza virusHAprotein
were observed in both groups of rats that received pre-
nebulized and post-nebulized pDNA vaccinations, com-
pared to the vehicle-only control group (Figure 7, p <
0.001). Importantly, no differences in IgG or IgA levels
(p > 0.05 in both cases) were observed between the
groups that received the nebulized and non-nebulized
form of the pDNA vaccine.
Antibody responses detected in sera following lung
instillation with the pDNA vaccine showed clear func-
tional activity in the hemagglutination inhibition (HAI)
assay (Table 2). Both groups that received pDNA vaccine
achieved appropriate HAI titers at levels considered to
be protective by the World Health Organization (WHO)
[29] in establishing immunity in humans. Compared to
the control group, serum from rats immunized with
pDNA via intratracheal instillation showed significantly
increased HAI activity (p < 0.001), with no difference
seen between the pre-nebulized and post-nebulized forms
of pDNA.
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Figure 4 SAW nebulization preserves the integrity of pDNA. Atomic force microscopy (a, b) and ethidium bromide agarose gel electrophoresis
(c) of pVR1020–PyMSP4/5 (a) before and (b) after nebulization. Lane M: 1 kbp DNA ladder; control lanes 1 and 4, recovered pDNA post-30 MHz
lanes 2 and 5, and post-20 MHz SAW nebulization lanes 3 and 6 are each at 85 and 50 μg/ml concentrations, respectively. The proportion of (d)
supercoiled (SC), open circular (OC) and fragmented pDNA quantifies the damage (n = 3). Bars represent the mean of trplicate samples with error
bars indicating the standard error of the mean. Data is representative of three independent experiments.
Aerosolized pDNA vaccination induces antibodies in sheep
Sheep were used to assess the efficacy of SAW-nebulized
airway administration of pDNA in a large animal model
with similar lung physiology to humans [30]. The sheep
were administered three airway immunizations at three-
week intervals using a 30MHz SAWdevice, nebulizing the
pDNA solution at approximately 110 μ/min. The aver-
age dose of pDNA delivered to the airways was 156±44μg
(mean± S.D.; data not shown). SAW-nebulized pDNA
delivered to the sheep airways induced significant HAI
activity, with a mean HAI titer of 192±74 (n = 4), in sera
collected one week after the third immunization (Table 3),
and was comparable to the outcome observed in rats (see
Table 2).
Discussion
In this study, we demonstrate the use of a SAW nebu-
lization device for the generation of aerosolized pDNA
with suitable size and stability characteristics to facili-
tate effective pulmonary delivery particularly for influenza
vaccination. The in vivo studies conducted showed for
the first time, successful delivery of the SAW-generated
pDNA to the airways of mice, rats, and importantly, in a
large animal model (sheep).
Generation of SAW nebulized droplets effective for deep
lung deposition
The generation of aqueous pDNA aerosol droplets with
sizes smaller than the 5 μm diameter required for optimal
deposition in the deep lung region [31] is particularly dif-
ficult due to the high surface tension of water [19]. The
nebulized droplet size is independent of excitation fre-
quency, but strongly dependent on fluid characteristics
to provide a route to effectively tune droplet size [17].
During SAW nebulization, the droplet size formed from
the device is governed by the wavelength of the capil-
lary waves generated on the surface of the source drop
[19]. The wavelength in turn, is predicted by the balance
between the capillary and viscous forces that dominate
at the surface such that the droplet diameter could be
lowered by increasing the surface tension and dynamic
viscosity of the source drop [19]. In the present study,
glycerol, known to be safe in aerosol form [32], was intro-
duced to modify the viscosity. The concentration of the
pDNA had a minor effect on the droplet diameter that can
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Figure 5 Administration of nebulized pDNA induces gene expression in the murine lung. Confocal microscopy of mouse lung parenchyma
cryosections 24 hours after (a, b, c) dosage of 75 μg with post-nebulized pVR1020–YFP in 0.9% NaCl aqueous solution, compared to an (d, e, f)
untreated case (scale bars: 100μm). The lung structure (a, d) and (b, e) cell nuclei are indicated with a counterstain of hematoxylin and eosin, and
with DAPI, respectively. Lung cells expressing YFP from instilled pVR1020–YFP appear green in (c) the treated lung sample; note the absence of
green in the (f) untreated sample. The control lung samples were imaged at a higher resolution to confirm the absence of YFP response.
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Figure 6 YFP is expressed in the epithelial cells of the terminal airways. YFP expression patterns observed using confocal microscopy of mouse
lung parenchyma cryosections 24 hours after (a, b and c) dosage of 75 μg with post-nebulized pVR1020–YFP in 0.9% NaCl aqueous solution
showing (a) YFP expression in a cluster of epithelial cells where lung cell nuclei stained with DAPI dilactate appear blue while cells expressing YFP
appear green (scale bar = 5 μm); (b) another view of a part of the YFP-expressing cell region shows the YFP distribution in the cells with
appropriate filtering to (b) show only the nuclei and (c) YFP (scale bar = 5 μm). (d)Western blot of the supernatant obtained from homogenized
mice lungs harvested (left lane) 24 hours post-transfection with 300μg pVR1020–YFP plasmid that was SAW nebulized at 30 MHz and instilled,
compared to (right lane) the supernatant from untreated mice lungs. The YFP protein appears clearly at 27 kDa. The additional protein bands
present at 50 and 37 kDa for both groups are due to the polyclonal nature of the rabbit anti-YFP antisera used as the probe where cross-reactivity
was induced across other serum proteins.
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Figure 7 Pulmonary delivery of pVR1020-HA pDNA induces antibody response in rats. Systemic and mucosal (a) IgG and (b) IgA antibody
responses detected in the sera of female Sprague-Dawley rats (n = 8 per group) 3 weeks following 300μg pVR1020-HA pDNA vaccination (primary
immunization) encoding an influenza A virus surface antigen, human hemagglutinin (HA) via lung instillation. Bars represent the mean ± SD and
individual rats are indicated as symbols. No significant (NS) difference between the pre and post-SAW nebulized vaccine instillation was found
(p = 0.163 for IgG and p = 0.486 for IgA, respectively), and a significant difference between these and the naïve rat was found (p < 0.001). Note that
the antibody response detected in the naïve rat group represents the detection limit of the assay.
be addressed by changing the glycerol concentration. By
employing 20% glycerol in the pDNA stock solution, the
SAW nebulizer delivered droplets with a mean diameter
less than 5 μm, which is required for effective deep lung
deposition.
SAW nebulization preserves the DNA integrity
Compact supercoiled DNA is the most immunogenic
form and, according to FDA requirements, must be
present at >80% in a licensable vaccine [33,34]. The
SAW nebulization process is verified in this study to pre-
serve the DNA integrity, where more than 90% of the
initial supercoiled pDNA was still present after SAW
nebulization. Scission of one of the two strands of the
pDNA releases torsional energy stored in the supercoiled
plasmid, and causing it to relax into an open circu-
lar form, while scission of both strands resuls in a lin-
ear polynucleotide and subsequent DNA fragments [35].
AFM and ethidium bromide agarose gel electrophoresis
of the pDNA (pVR1020–PyMSP4/5) before and after
SAW nebulization showed that the tightly twisted super-
coiled geometry of the pDNA was effectively maintained.
The AFM images nevertheless showed some morpho-
logical differences between the non-nebulized and SAW-
nebulized pDNA, where the later showed aggregated
structures commonly induced during nebulization pro-
cesses [36], presumed to be tightly twisted strands of
pDNA. The frequency of the SAW nebulizer had little
effect on the results, and likewise, pDNA concentrations
in the source drop prior to nebulization (5 to 85 μg/ml)
had minimal effect on the percentage of supercoiled
pDNA left after nebulization.
A small proportion of the pDNA prior to SAW nebu-
lization was found to be fragmented, most likely occurring
during plasmid purification and preparation. This was
especially evident at a pDNA concentration of 5 μg/ml,
with around 50% and 20% of supercoiled and fragmented
pDNA, respectively. Linear, double-stranded DNA is
Table 2 Hemagglutination inhibition activity after lung immunization of rats
Rat Naïve Pre-nebulized Post-nebulized
No. Pre Post Pre Post Pre Post
Vaccination Vaccination Vaccination Vaccination Vaccination Vaccination
Titer Titer Titer Titer Titer Titer
1 < 5 < 5 < 5 800 < 5 800
2 < 5 < 5 < 5 1600 < 5 800
3 < 5 < 5 < 5 1600 < 5 800
4 < 5 < 5 < 5 1600 < 5 1600
5 < 5 < 5 < 5 1600 < 5 1600
6 < 5 < 5 < 5 1600 < 5 1600
7 < 5 < 5 < 5 1600 < 5 1600
8 < 5 < 5 < 5 1600 < 5 1600
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Table 3 Hemagglutination inhibition activity after
pulmonary aerosol immunization of sheep
Sheep Pre Post
No. Vaccination Vaccination
Titer Titer
1 < 1 256
2 < 1 128
3 < 1 256
4 < 1 128
very susceptible to flow-induced stresses. For example,
minor differences in their characteristic dimension that
arise from scission have large effects on their response
to hydrodynamic stresses [37]. Stretching hydrodynamic
forces of only 0.3 nN, well below the 1.6–5.0 nN required
to break the covalent bonds within, are known to cause
irreversible strand separation and formation of nicks,
degrading the pDNA [9]. Though cavitation is absent in
SAW nebulization [19], accelerations in the fluid of 107–
108 m/s2 are typically due to the MHz-order frequencies
used. If the relaxed forms of the pDNA are adjacent to
the fluid interface, it is possible that the gradient in the
acceleration and consequently the shear stress across the
pDNA molecules is sufficient to cause further damage,
though the relaxation time scale of the fluid shear,∼ 10 ns,
is two orders of magnitude smaller than that required
to shear large molecules, suggesting the risk of denatur-
ing molecules such as DNA [38] is negligible. Compared
to standard ultrasonic nebulization at 20–80 kHz, where
cavitation is prevalent and large molecules like pDNA
in solution actually serve as cavitation bubble nucle-
ation sites [10] and cause wholesale destruction of such
molecules, the damage caused by SAW nebulization is
minor. For 5 kbp plasmids, the percentage of fragmented
pDNA after nebulization is lower with SAW (< 20%) than
with conventional (> 35%) or vibrating mesh nebuliz-
ers (> 40%) [39]. Hence, the SAW nebulization approach
has several key advantages over the current generation
of ultrasonic medical nebulizers for the delivery of large
molecules [19].
We set out to test the capacity of nebulized DNA
to induce immune responses in-vivo. Previous studies
using small animal models to investigate aerosol deliv-
ery of pDNA formulations have found it difficult to
effectively control the delivered dose via nebulization [40].
Hence preliminary experiments in these animals involved
recovery of the nebulized material followed by intratra-
cheal instillation of the condensate. When post-nebulized
pVR1020–YFP plasmid was introduced into the lungs of
mice, the expression of yellow fluorescent protein (YFP)
provided evidence of transfection that was entirely absent
in the lungs of untreated mice. We hypothesize that the
expression of YFP which appears as discrete aggregates
with granular appearance was presumably close to the
epithelium of the conducting airways, consistent with
gene expression patterns following DNA vaccination in
mouse lungs in another study [12]. Furthermore, Western
blot analysis confirmed the presence of the YFP only in the
lungs of treated lungs.
SAW nebulizedDNA induces protective antibodies after
pulmonary delivery
More importantly, our data showed that SAW nebuliza-
tion did not inhibit the ability of the vaccine to induce
protective antibodies. Anti-HA antibody titers detected
here were found to be comparable to the vaccination out-
comes using a similar pDNA influenza vaccine complexed
with polyethyleimine (PEI) [12]. Our results suggest that
naked pDNA can be effectively delivered to the lung with
subsequent transfection into airway cells (despite likely
degradation of the pDNA) while also demonstrating pre-
served immunogenicity of the DNA vaccine subjected to
the SAW nebulization process.
Following pDNA vaccination in rats, serum hemagglu-
tination inhibition (HAI) titers were significantly greater
than 40, levels considered to be protective according to
WHO standards [29] and indicative of what would trans-
late into a significant humoral response elicited to admin-
istered pDNA. These results are particularly encouraging
when compared elsewhere to the outcome of vaccina-
tion with pDNA encoding swine H1N1 complexed with
PEI and administered intranasally to BALB/c mice [41].
Although low doses of pDNA were used in this study,
some synthetic adjuvants such as PEI are known to be
highly cytotoxic [15], and are likely to encounter problems
with approval for human use. Our results in sheep also
compare well to the administration of HA protein in sheep
via subcutaneous injection and via intratracheal instilla-
tion to the lung that resulted in HAI titers of 95 to 122
[42].
Translation of successful outcomes with DNA vaccina-
tion seen in small (rodent) to larger animal models [43]
including humans [44] continues to represent a major
hurdle in this emerging field. The similarities in size,
structure and physiology of sheep and human lungs [30]
suggests that sheep could be used as a relevant large
animal model to test the efficacy of pulmonary DNA vac-
cination for human applications. In the present study,
the SAW nebulized pDNA induced a robust antibody
responsewhen delivered into the lungs of conscious sheep
under mechanical respiration, with similar levels in anti-
body response to that observed in rats. Given the scope of
the current study, we have not included the impactor mea-
surement data. However, the sheep aerosol study confirms
that the aerosols generated by SAW were indeed suited
for deep lung delivery (droplet size range 0.5-5 μm),
Rajapaksa et al. Respiratory Research 2014, 15:60 Page 11 of 12
http://respiratory-research.com/content/15/1/60
evidenced by the HAI assays and the induction of the
functional antibodies.
This study reports the first instance of successful pDNA
delivery via inhalation using an unprotected pDNA vac-
cine in a clinically relevant large animal model. Due to
similarities with humans in lung structure and physiol-
ogy, sheep provide a better preclinical model than smaller
animals for the optimization of nebulizers intended for
lung gene delivery. Studies presented here and elsewhere
indicate that sheep are proving to be an invaluable model
for the assessment of gene therapy efficacy, the delivery
profile of the nebulizer to suit conventional sized devices
and the safety of the gene transfer protocol, all criti-
cally relevant endpoint measurements [45]. Further, the
present findings suggest that the SAWnebulizermay serve
to effectively deliver pDNA vaccines that can be rapidly
produced upon demand. This represents a significant out-
come in the context of ensuring a timely response to
pandemic disease outbreaks, and in the developing world
where there is neither a sufficient health workforce nor
access to safe injection methods.
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